InnoCare Pharma (9969.HK) Earnings Review Summary Company Overview - **Company**: InnoCare Pharma (9969.HK) - **Industry**: Biotechnology Key Financial Highlights - **3Q Orela Sales**: Rmb383 million, representing a **39% year-over-year (y/y)** increase and **18% quarter-over-quarter (q/q)** growth, compared to **4% q/q** in 2Q25 [1] - **Net Loss**: Reduced to **-Rmb34 million** from **-Rmb48 million** in 2Q25, with slower growth in Selling, General and Administrative (SG&A) expenses at **19% y/y** [1] - **2025 Guidance**: Management raised orela sales growth guidance to **40% y/y** from the previous **35% y/y** [1] Growth Drivers - **Hospital Coverage**: Expansion in low-tier markets contributed to sales growth [1] - **MZL Growth**: Solid growth in MZL accounted for approximately **40%** of new patient acquisitions [1] - **Future Sales Momentum**: Expected continued growth in orela sales in 2026E at **28% y/y**, driven by newly reimbursed 1L CLL/SLL indication [1] New Product Development - **Tafasitamab**: Targeting the self-pay market with expected sales of **Rmb100 million to Rmb200 million** in 2026 [1] - **Immunology Pipeline**: Ongoing development with multiple catalysts: - **ICP-332**: Phase 3 data on AD expected by week 16 and phase 2 data for vitiligo in mid-2026 [3] - **ICP-488**: Phase 3 trial for psoriasis aiming for patient enrollment completion by year-end 2025 [3] - **Orelabrutinib**: Phase 2b data for SLE to be released in 4Q25 [3] Profitability Outlook - **Profitability Expectations**: Management anticipates turning profitable in 2025 post-Zenas deal, with core business profits expected by 2027 [2] - **R&D Expenses**: Projected at nearly **Rmb1 billion** for 2025, with a **15% y/y** growth expected for 2026 [2] - **Selling Expenses**: Anticipated growth of **35%-40% y/y** in 2026 to support the commercial launch of ITP indication in 2027 [2] Price Target and Risks - **12-Month Price Target**: Revised to **HK$24.54** for H-Share and **Rmb47.28** for A-Share, reflecting an **upside of 61.8%** and **86.6%** respectively [9][11] - **Key Risks**: Include R&D risks for clinical assets, uncertainties in pricing, potential entry of generic ibrutinib in 2027, and below-expected progress in global expansion [10] Conclusion - InnoCare Pharma shows strong sales growth and a promising pipeline, with management optimistic about future profitability and market expansion. The raised guidance and ongoing clinical trials position the company favorably within the biotechnology sector.